2′-chloroacetylenyl substituted nucleoside derivatives

A compound represented by Formula (I):

• or the β-L enantiomer thereof, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, or combination thereof, wherein:
• R1 is selected from the group consisting of:
• 1) hydrogen;
• 2) —N;
• 3) halogen;
• 4) —N3;
• and
• 5) Substituted or unsubstituted —C1-C8 alkyl;
• R2 is selected from the group consisting of:
• 1) halogen;
• 2) —CN;
• 3) —N3;
• and
• 4) OR6;
• where R6 is selected from the group consisting of:
• hydrogen, hydroxy protecting group, —C(O)R7, —C(O)OR7, and —C(O)NR8aR8b;
• wherein R7 is selected from the group consisting of:
• substituted or unsubstituted —C1-C8 alkyl, substituted or unsubstituted —C2-C8 alkenyl, substituted or unsubstituted —C2-C8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic;
• R8a and R8b are each independently selected from the group consisting of:
• hydrogen and R7;
• or alternatively R8a and R8b taken together with the nitrogen atom to which they are attached form a heterocyclic ring;
• R4a is selected from the group consisting of:
• 1) halogen;
• 2) hydrogen;
• 3) —CN;
• 4) —N3;
• and
• 5) OR6;
• R3 is R6;
• or alternatively R2 is —OR6 and R3 and R6 together form a group selected from:
• —C(Me)2-, —C(CH2)4—, —CH(Ph)-, —CH(OMe)- and —P(O)(OH)—;
• B is selected from the group consisting of:
• substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic;
• R5a and R5b are independently selected from the group consisting of:
• 1) hydrogen;
• 2) substituted or unsubstituted —C1-C8 alkyl;
• 3) substituted or unsubstituted —C2-C8 alkenyl;
• 4) substituted or unsubstituted —C2-C8 alkynyl;
• 5) or R5a and R5b are taken together with the carbon atom to which they are attached to form a group selected from —C3-C8 cycloalkyl, —C3-C8 cycloalkenyl, or —C3-C8 cycloalkynyl;
• R5 is selected from the group consisting of:
• 1) hydrogen;
• 2) R6;
• 3) —P(O)(OR7a)(OR7b);
• wherein R7a and R7b are each independently selected from the group consisting of a) hydrogen;
• b) unsubstituted or substituted —C1-C8 alkyl;
• 4) —P(O)(OR7a)—O—P(O)(OR7b)(OR7c);
• wherein R7a and R7b are previously defined;
• R7c is selected from the group consisting of a) hydrogen;
• b) unsubstituted or substituted —C1-C8 alkyl;
• 5) —P(O)(OR7a)—O—P(O)(OR7b)—O—P(O)(OR7c)(OR7d);
• wherein R7a, R7b and R7c are previously defined;
• R7d is selected from the group consisting of a) hydrogen;
• b) unsubstituted or substituted —C1-C8 alkyl;
• 6)
• where X is O or S;
• R9 is R7 wherein R7 is previously defined;
• R10, R11 and R12 are each independently selected from the group consisting of:
• a) hydrogen;
• and b) unsubstituted or substituted —C1-C8 alkyl;
• or R11 is hydrogen, and R12 and R10 taken together with the nitrogen which R10 is attached to form a heterocyclic ring;
• or R11 and R12 taken together with the carbon which they are attached form a ring;
• R13 is hydrogen or R7, wherein R7 is previously defined;
• and
• 7)
• where X is O or S;
• n is 1-4;
• R8a and R8b are as previously defined;
• R14 is hydrogen or —(CO)—R7, wherein R7 is as previously defined;
• Or, R5 and R3 are taken together to form
• where X is O or S;
• and R6 is as previously defined.